EGFR突變NSCLC診療進(jìn)展盤點(diǎn)，埃萬妥單抗聯(lián)合療法對(duì)治療格局的影響

從晚期二線到一線，EGFR/MET雙特異性抗體埃萬妥單抗正在重塑EGFR突變晚期非小細(xì)胞肺癌的治療路徑，為"慢病化"管理目標(biāo)提供全新解決方案！

*以下內(nèi)容僅供醫(yī)療衛(wèi)生專業(yè)人士瀏覽。

參考文獻(xiàn)：

[1] Han B, Zheng R, Zeng H, et al. Cancer incidence and mortality in China, 2022[J]. J Natl Cancer Cent. 2024 Feb 2;4(1):47-53.

[2] Gillespie CS, Mustafa MA, Richardson GE, et al. Genomic Alterations and the Incidence of Brain Metastases in Advanced and Metastatic NSCLC: A Systematic Review and Meta-Analysis[J]. J Thorac Oncol. 2023;S1556-0864(23)00638-X.

[3] Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer[J]. N Engl J Med. 2018 Jan 11;378(2):113-125.

[4] Ramalingam SS, Vansteenkiste J, Planchard D, et al. Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC[J]. N Engl J Med. 2020 Jan 2;382(1):41-50.

[5] Qing Zhou, Hongyun Zhao, Shun Lu, et al. Consensus on the lung cancer management after third-generation EGFR-TKI resistance. Lancet Reg Health West Pac. 2024 Dec 11:53:101260.

[6] N Peled, A Tufman, L V Sequist, et al. COMPEL: osimertinib plus platinum-based chemotherapy in patients with EGFR-mutated advanced NSCLC and progression on first-line Osimertinib[J]. ESMO Open. 2025 Oct;10(10):105807. doi: 10.1016/j.esmoop.2025.105807.

[7] Shih J, Wang J, Wang Y, et al. Amivantamab plus chemotherapy vs chemotherapy among Asian patients with EGFR-mutant advanced NSCLC after progression on osimertinib: A MARIPOSA-2 subgroup analysis. 2023 ESMO Asia. LBA11.

[8] Passaro A, et al. Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study[J]. Ann Oncol. 2024 Jan;35(1):77-90.

[9] Riihimaki M, Hemminki A, Fallah M, et al. Metastatic sites and survival in lung cancer [J] . Lung Cancer,2014,86(1):78 -84.

[10] Paul Stockhammer, Michael Grant, Anna Wurtz, et al. Co-Occurring Alterations in Multiple Tumor Suppressor Genes Are Associated With Worse Outcomes in Patients With EGFR-Mutant Lung Cancer[J]. J Thorac Oncol. 2024 Feb;19(2):240-251.

[11] E Felip, B C Cho, V Gutiérrez, et al. Amivantamab Plus Lazertinib vs Osimertinib in First-line EGFR-mutant Advanced NSCLC: Longer Follow-up of the MARIPOSA Study[J]. Ann Oncol. 2024 Sep;35(9):805-816..

[12] J.C-H. Yang, Y.J. Kim, S-H. Lee, et al. Amivantamab plus lazertinib vs osimertinib in first-line (1L) EGFR-mutant (EGFRm) advanced NSCLC: Final overall survival (OS) from the phase III MARIPOSA study. 2025 ELCC. 4O.

[13] Felip E, B C Cho, V Gutiérrez, et al. Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA[J]. Ann Oncol. 2024;35(9):805-816.

[14] Alexander I Spira, Luis Paz-Ares, Ji-Youn Han, et al. Preventing Infusion-Related Reactions With Intravenous Amivantamab-Results From SKIPPirr, a Phase 2 Study: A Brief Report[J]. J Thorac Oncol. 2025 Jun;20(6):809-816.

[15] Nicolas Girard, Weimin Li, Alexander I Spira, et al. Preventing Moderate to Severe Dermatologic Adverse Events in First-lineEGFR-mutant Advanced NSCLC Treated with Amivantamab Plus Lazertinib. 2025 ELCC. 10MO.

審批編碼：CP-556188

批準(zhǔn)分發(fā)日期：12/6/2025

有效期：12/6/2026

*“醫(yī)學(xué)界”力求所發(fā)表內(nèi)容專業(yè)、可靠，但不對(duì)內(nèi)容的準(zhǔn)確性做出承諾；請(qǐng)相關(guān)各方在采用或以此作為決策依據(jù)時(shí)另行核查。